Cargando…

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations

PURPOSE: To assess the efficacy and safety of neoadjuvant docetaxel + cisplatin chemotherapy with androgen deprivation therapy for the treatment of locally advanced prostate cancer (PCa) in patients harboring germline DNA damage repair genes (gDDR) defects. METHODS: We conducted a prospective observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Chenfei, Liu, Jiazhou, Fan, Liancheng, Zhu, Yinjie, Wang, Yanqing, Sha, Jianjun, Huang, Yiran, Dong, Baijun, Pan, Jiahua, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527989/
https://www.ncbi.nlm.nih.gov/pubmed/36199621
http://dx.doi.org/10.1177/17588359221128356
_version_ 1784801198470070272
author Chi, Chenfei
Liu, Jiazhou
Fan, Liancheng
Zhu, Yinjie
Wang, Yanqing
Sha, Jianjun
Huang, Yiran
Dong, Baijun
Pan, Jiahua
Xue, Wei
author_facet Chi, Chenfei
Liu, Jiazhou
Fan, Liancheng
Zhu, Yinjie
Wang, Yanqing
Sha, Jianjun
Huang, Yiran
Dong, Baijun
Pan, Jiahua
Xue, Wei
author_sort Chi, Chenfei
collection PubMed
description PURPOSE: To assess the efficacy and safety of neoadjuvant docetaxel + cisplatin chemotherapy with androgen deprivation therapy for the treatment of locally advanced prostate cancer (PCa) in patients harboring germline DNA damage repair genes (gDDR) defects. METHODS: We conducted a prospective observational study in patients with locally advanced PCa confirmed with gDDR defects through next-generation sequencing. All patients received either docetaxel + cisplatin (platinum-group) or docetaxel chemo-hormonal therapy (docetaxel group) followed by radical prostatectomy with extended lymphadenectomy. The primary end point was biochemical progression-free survival (bPFS) and secondary end points include postoperative pathological response and safety assessment during the study period. RESULTS: A total of 36 patients were included in the study, among whom 14 and 22 patients received docetaxel + cisplatin and docetaxel treatment, respectively. Down-staging of Tumor (T), Nodes (N), and Metastasis (M) stages was observed in 11 (78.57%) and 9 (40.9%) patients (p = 0.041), respectively, in the docetaxel + cisplatin group and docetaxel group. The median bPFS was 7.76 months (95% CI 0.770–14.748) and not reached in the docetaxel group and docetaxel + cisplatin group, respectively. bPFS was significantly longer in the docetaxel + cisplatin group (p = 0.039) with a hazard ratio of 0.386 (95% CI 0.151–0.987, p < 0.05). Furthermore, one patient discontinued docetaxel + cisplatin after second cycle due to severe liver insufficiency which was confirmed as viral hepatitis A and no significant perioperative complications was observed in either group. CONCLUSION: This study suggests that cisplatin may increase docetaxel anticancer activity with tolerable safety profile in patients with locally advanced PCa carrying gDDR defects in the neoadjuvant setting, a hypothesis which will require prospective, randomized confirmation.
format Online
Article
Text
id pubmed-9527989
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-95279892022-10-04 Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations Chi, Chenfei Liu, Jiazhou Fan, Liancheng Zhu, Yinjie Wang, Yanqing Sha, Jianjun Huang, Yiran Dong, Baijun Pan, Jiahua Xue, Wei Ther Adv Med Oncol Original Research PURPOSE: To assess the efficacy and safety of neoadjuvant docetaxel + cisplatin chemotherapy with androgen deprivation therapy for the treatment of locally advanced prostate cancer (PCa) in patients harboring germline DNA damage repair genes (gDDR) defects. METHODS: We conducted a prospective observational study in patients with locally advanced PCa confirmed with gDDR defects through next-generation sequencing. All patients received either docetaxel + cisplatin (platinum-group) or docetaxel chemo-hormonal therapy (docetaxel group) followed by radical prostatectomy with extended lymphadenectomy. The primary end point was biochemical progression-free survival (bPFS) and secondary end points include postoperative pathological response and safety assessment during the study period. RESULTS: A total of 36 patients were included in the study, among whom 14 and 22 patients received docetaxel + cisplatin and docetaxel treatment, respectively. Down-staging of Tumor (T), Nodes (N), and Metastasis (M) stages was observed in 11 (78.57%) and 9 (40.9%) patients (p = 0.041), respectively, in the docetaxel + cisplatin group and docetaxel group. The median bPFS was 7.76 months (95% CI 0.770–14.748) and not reached in the docetaxel group and docetaxel + cisplatin group, respectively. bPFS was significantly longer in the docetaxel + cisplatin group (p = 0.039) with a hazard ratio of 0.386 (95% CI 0.151–0.987, p < 0.05). Furthermore, one patient discontinued docetaxel + cisplatin after second cycle due to severe liver insufficiency which was confirmed as viral hepatitis A and no significant perioperative complications was observed in either group. CONCLUSION: This study suggests that cisplatin may increase docetaxel anticancer activity with tolerable safety profile in patients with locally advanced PCa carrying gDDR defects in the neoadjuvant setting, a hypothesis which will require prospective, randomized confirmation. SAGE Publications 2022-09-30 /pmc/articles/PMC9527989/ /pubmed/36199621 http://dx.doi.org/10.1177/17588359221128356 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Chi, Chenfei
Liu, Jiazhou
Fan, Liancheng
Zhu, Yinjie
Wang, Yanqing
Sha, Jianjun
Huang, Yiran
Dong, Baijun
Pan, Jiahua
Xue, Wei
Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
title Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
title_full Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
title_fullStr Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
title_full_unstemmed Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
title_short Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
title_sort efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline dna damage repair gene alterations
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527989/
https://www.ncbi.nlm.nih.gov/pubmed/36199621
http://dx.doi.org/10.1177/17588359221128356
work_keys_str_mv AT chichenfei efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations
AT liujiazhou efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations
AT fanliancheng efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations
AT zhuyinjie efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations
AT wangyanqing efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations
AT shajianjun efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations
AT huangyiran efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations
AT dongbaijun efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations
AT panjiahua efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations
AT xuewei efficacyofneoadjuvantdocetaxelcisplatinchemohormonaltherapyversusdocetaxelchemohormonaltherapyinpatientswithlocallyadvancedprostatecancerwithgermlinednadamagerepairgenealterations